Discovery of novel benzohydroxamate-based histone deacetylase 6 (HDAC6) inhibitors with the ability to potentiate anti-PD-L1 immunotherapy in melanoma
作者:Xiaopeng Peng、Ziwen Yu、Goverdhan Surineni、Bulian Deng、Meizhu Zhang、Chuan Li、Zhiqiang Sun、Wanyi Pan、Yao Liu、Shenglan Liu、Bin Yu、Jianjun Chen
DOI:10.1080/14756366.2023.2201408
日期:2023.12.31
Abstract In this study, a novel series of histone deacetylases 6 (HDAC6) inhibitors containing polycyclic aromatic rings were discovered and evaluated for their pharmacological activities. The most potent compound 10c exhibited high HDAC6 inhibitory activity (IC50 = 261 nM) and excellent HDAC6 selectivity (SI = 109 for HDAC6 over HDAC3). 10c also showed decent antiproliferative activity in vitro with
抽象的 在这项研究中,发现了一系列含有多环芳环的新型组蛋白脱乙酰酶 6 (HDAC6) 抑制剂,并评估了其药理活性。最有效的化合物10c表现出高 HDAC6 抑制活性 (IC 50 = 261 nM) 和出色的 HDAC6 选择性 (HDAC6 相对于 HDAC3 的 SI = 109)。 10c还表现出良好的体外抗增殖活性,对四种癌细胞系的 IC 50为 7.37–21.84 μM,与图巴他汀 A 相当(平均 IC 50 = 6.10 μM)。进一步的机制研究表明, 10c有效诱导 B16-F10 细胞凋亡和 S 期停滞。此外, 10c在体外和体内均显着增加乙酰化-α-微管蛋白的表达,而不影响乙酰化-H3(HDAC1 抑制标志物)的水平。此外, 10c (80 mg/kg) 在黑色素瘤模型中表现出中等抗肿瘤功效,肿瘤生长抑制 (TGI) 为 32.9%,与图巴他汀 A (TGI = 31